Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity.
Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity.
复制标题
重组人白细胞介素 2 的每周重复周期：具有可接受毒性的肾癌反应。
DOI：
10.1093/jnci/80.1.60
复制
发表时间：
1988
期刊：
影响因子：
--
通讯作者：
Sondel,PM
中科院分区：
文献类型：
--
作者：
Sosman,JA;Kohler,PC;Hank,J;Moore,KH;Bechhofer,R;Storer,B;Sondel,PM
对23例转移癌患者进行了每周重复周期的人重组白细胞介素-2（IL-2）的I期试验。患者每周接受4天IL-2治疗，随后观察3天，连续4周。IL-2以1.0或3.0 × 106 U/m2/d的剂量通过三种方案之一（包括持续或推注）静脉内给药。所有治疗均在综合医院病房进行，无重症监护室监测或支持。17名患者患有转移性肾细胞癌;其中3名表现出可测量的（>50%缩小）部分缓解。这项研究表明，单独给予IL-2，而不需要淋巴因子激活的杀伤细胞，以这种方式可以诱导抗肿瘤作用，具有可接受的毒性。[J Natl Cancer Inst 1988;80：60-63]
A phase I trial of repetitive weekly cycles of human recombinant interleukin-2 (IL-2) was performed in 23 patients with metastatic carcinoma. Patients received 4 days of IL-2 each week, followed by 3 days of observation, for 4 consecutive weeks. IL-2 was administered iv at 1.0 or 3.0 × 106U/m2/day by one of three schedules involving continuous or bolus infusions. All treatment was carried out in a general hospital ward without intensive care unit monitoring or support. Seventeen patients had metastatic renal cell carcinoma; three of these demonstrated measurable (>50% shrinkage) partial responses. This study demonstrates that IL-2 given alone without lymphokine-activated killer cells in this manner can induce antitumor effects with acceptable toxicity. [J Natl Cancer Inst 1988;80:60-63]